Case 1. Increased dyspnea was noted while on sitagliptin (week 0). Peak flows increased rapidly within several days of stopping the drug. Restarting sitagliptin after 2 1/2 weeks led to a progressive, 30% decline in PEFR. PEFR again returned to her usual after stopping the drug (weeks 5 and 6).